Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 9c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.72), $0.09 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $1.27 million versus the consensus estimate of $11.16 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Deutsche Bank Starts DexCom (DXCM) at Buy